Table 1. Baseline characteristics.
| Atrial fibrillation | No | Yes | No | Yes |
|---|---|---|---|---|
| Chronic kidney disease | No | No | Yes | Yes |
| N = 9,268 | N = 374 | N = 2,427 | N = 325 | |
| Age (years) (IQR) | 55 (46–63) | 64 (58–70) | 64 (55–70) | 71 (65–75) |
| Sex, female (%) | 3203 (35%) | 88 (24%) | 881 (36%) | 91 (28%) |
| Body mass index (kg/m2) (IQR) | 26.2 (23.8–28.9) | 26.8 (24.5–29.9) | 26.8 (24.3–29.8) | 26.7 (24.2–29.6) |
| Waist circumference (cm) (IQR) | 93 (85–101) | 97 (90–106) | 96 (88–105) | 99 (90–107) |
| Hypertension (%) | 4523 (49%) | 224 (60%) | 1778 (73%) | 242 (74%) |
| Stroke (%) | 1000 (11%) | 65 (17%) | 327 (13%) | 51 (16%) |
| Myocardial infarction (%) | 1810 (20%) | 98 (26%) | 553 (23%) | 103 (32%) |
| Peripheral arterial disease (%) | 936 (10%) | 31 (8%) | 374 (15%) | 62 (19%) |
| Heart failure (%) | 67 (1%) | 8 (2%) | 57 (2%) | 26 (8%) |
| Diabetes mellitus (%) | 1354 (15%) | 66 (18%) | 659 (27%) | 102 (31%) |
| Antiplatelet drug use (%) | 4975 (54%) | 209 (56%) | 1428 (59%) | 159 (49%) |
| Anticoagulant use (%) | 448 (5%) | 170 (45%) | 215 (9%) | 157 (48%) |
| Statin use (%) | 4842 (52%) | 257 (69%) | 1381 (57%) | 193 (59%) |
| Total cholesterol (mmol/L) | 4.9 (4.2–5.9) | 4.6 (3.8–5.5) | 4.9 (4.1–5.9) | 4.9 (3.9–5.8) |
| HDL cholesterol (mmol/L) | 1.2 (1.0–1.5) | 1.2 (1.0–1.5) | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) |
| LDL cholesterol (mmol/L) | 2.9 (2.3–3.8) | 2.6 (2.0–3.4) | 2.8 (2.2–3.7) | 2.8 (2.0–3.7) |
| Triglycerides (mmol/L) (IQR) | 1.3 (1.0–2.0) | 1.3 (1.0–1.3) | 1.5 (1.1–2.3) | 1.5 (1.1–2.1) |
| Hemoglobin (mmol/L) (IQR) | 8.9 (8.4–9.4) | 9.0 (8.3–9.4) | 8.8 (8.1–9.3) | 8.6 (8.0–9.3) |
| eGFR (ml/min/1.73 m2) (IQR) | 85 (75–96) | 80 (70–88) | 58 (50–78) | 55 (46–65) |
Notes: Continuous variables are expressed as median with interquartile ranges (IQR).